Benzinga · Aug 14, 2026
JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9
JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the price target from $8 to $9.
UP
NASDAQ · UPB
Upstream Bio, Inc.
Healthcare · Biotechnology
$6.97
Up+$0.12 (+1.75%)
Updated Aug 22, 2026, 1:15 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.48B
- P/E ratio
- -14.14
- Dividend yield
- 0.00%
- 52-week range
- $5.85 – $10.67
- Volume
- 434.24K
- Avg. volume
- 437.05K
Price performance
UPB price history
1M range · 21 trading sessions · Daily adjusted prices
UPB closed at $6.97 after 21 trading sessions, up 8.74% for the selected period.
- Last close
- $6.97
- Period change
- +8.74%
- Period low
- $6.31
- Period high
- $7.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $6.91 | $7.0062 | $6.85 | $6.97 | 434.24K |
| Aug 20, 2026 | $7.48 | $7.555 | $6.745 | $6.85 | 592.94K |
| Aug 19, 2026 | $7.04 | $7.53 | $6.91 | $7.515 | 574.18K |
| Aug 18, 2026 | $7.28 | $7.435 | $6.73 | $6.85 | 461.78K |
| Aug 17, 2026 | $7.02 | $7.19 | $6.86 | $7.14 | 852.44K |
| Aug 14, 2026 | $6.95 | $7.14 | $6.80 | $7.07 | 688.25K |
| Aug 13, 2026 | $7.02 | $7.04 | $6.87 | $6.91 | 378.84K |
| Aug 12, 2026 | $7.00 | $7.25 | $6.84 | $6.91 | 635.22K |
| Aug 11, 2026 | $7.48 | $7.70 | $7.01 | $7.09 | 628.06K |
| Aug 10, 2026 | $7.32 | $7.62 | $7.20 | $7.44 | 869.59K |
| Aug 7, 2026 | $6.94 | $7.26 | $6.89 | $7.25 | 621.85K |
| Aug 6, 2026 | $6.75 | $7.1658 | $6.66 | $6.87 | 427.17K |
| Aug 5, 2026 | $6.77 | $6.88 | $6.58 | $6.74 | 917.31K |
| Aug 4, 2026 | $6.40 | $6.915 | $6.40 | $6.79 | 1.36M |
| Aug 3, 2026 | $6.31 | $6.43 | $6.175 | $6.42 | 774.29K |
| Jul 31, 2026 | $6.58 | $6.6875 | $6.29 | $6.31 | 297.71K |
| Jul 30, 2026 | $6.35 | $6.665 | $6.29 | $6.57 | 320.72K |
| Jul 29, 2026 | $6.39 | $6.48 | $6.21 | $6.41 | 702.78K |
| Jul 28, 2026 | $6.40 | $6.54 | $6.09 | $6.40 | 433.23K |
| Jul 27, 2026 | $6.47 | $6.60 | $6.26 | $6.40 | 459.48K |
| Jul 24, 2026 | $6.40 | $6.61 | $6.16 | $6.41 | 626.43K |
Latest UPB news
The latest Smart Investors Daily articles mentioning UPB.
Stock researchCompany · Overview
UPB research
Overview
Company profile and research snapshot.
Company profile
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $47.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | JP Morgan | Neutral | — |
| Aug 12, 2026 | Truist Securities | Buy | — |
| Jun 12, 2026 | JP Morgan | Neutral | — |
| Jun 3, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | Mizuho | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Truist Securities Maintains Buy on Upstream Bio, Lowers Price Target to $25
Truist Securities analyst Danielle Brill maintains Upstream Bio (NASDAQ:UPB) with a Buy and lowers the price target from $43 to $25.
Yahoo · Aug 11, 2026
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Aug 11, 2026
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track – – Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 – – Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications – WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Upstream Bio,
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
